Drug Profile
Gallium-68 PSMA R2 - Advanced Accelerator Applications
Alternative Names: 68Ga-PSMA-R2; Ga68-PSMA-R2Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer Advanced Accelerator Applications
- Class Antineoplastics; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 15 Dec 2020 Phase-II clinical trials in Prostate cancer (Diagnosis) in USA (unspecified route) (NCT03698370)
- 20 Aug 2019 Advanced Accelerator Applications completes the phase I/II PROfind trial for Prostate cancer (Diagnosis, Hormone refractory, Metastatic disease) in USA (NCT03490032)
- 05 Feb 2019 Advanced Accelerator Applications re-initiates the phase I/II PROfind trial for Prostate cancer in USA (NCT03490032)